Artificial Intelligence (AI) Enabled Pharma Supply Chain Market Global Report 2026

The artificial intelligence (AI) enabled pharma supply chain market size has grown rapidly in recent years. It will grow from $1.1 billion in 2025 to $1.27 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to manual pharmaceutical supply chain operations, fragmented global drug distribution networks, limited adoption of digital tracking systems, paper-based inventory and procurement processes, reactive demand planning during healthcare crises.

The artificial intelligence (AI) enabled pharma supply chain market size is expected to see rapid growth in the next few years. It will grow to $2.23 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to rapid adoption of ai-driven predictive supply chain platforms, expansion of biologics and personalized medicine distribution, increasing regulatory compliance and traceability requirements, growth of cold chain logistics for temperature-sensitive drugs, rising integration of iot-enabled real-time tracking and monitoring systems. Major trends in the forecast period include decentralized pharmaceutical manufacturing and regional production expansion, surge in epidemic-driven demand volatility and preparedness planning, increasing complexity in biologics and temperature-sensitive drug logistics, stricter pharmaceutical quality assurance and compliance documentation requirements, growing dependence on specialized pharmaceutical third-party logistics and outsourcing networks.

The increasing adoption of personalized medicines is expected to propel the growth of the artificial intelligence (AI)-enabled pharma supply chain market going forward. Personalized medicine refers to a healthcare approach that tailors therapeutic interventions to individual patient profiles by utilizing genetic, biomarker, and clinical data to improve treatment precision and outcomes. The increasing adoption of personalized medicines is driven by advancements in genomics and molecular biology, which enable the precise identification of genetic and molecular differences among patients to tailor treatments for greater effectiveness and safety. Artificial intelligence (AI)-enabled pharma supply chains support personalized medicines by leveraging real-time data integration, predictive analytics, and precise demand and supply alignment to ensure the right therapy is manufactured, distributed, and delivered to individual patients in a timely and efficient manner. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, representing a significant increase from the six approvals recorded in 2022. Therefore, the increasing adoption of personalized medicines is driving the growth of the artificial intelligence (AI)-enabled pharma supply chain market.

Leading companies operating in the artificial intelligence (AI) enabled pharma supply chain market are focusing on developing innovative solutions, such as predictive supply chain analytics, to anticipate demand fluctuations, optimize inventory levels, and enhance end-to-end visibility for improved efficiency and reduced operational risks. Predictive supply chain analytics is the use of artificial intelligence, machine learning, and historical plus real-time data to forecast future demand, disruptions, and inventory needs, enabling companies to make proactive and more efficient supply chain decisions. For example, in April 2024, Lonza Group AG, a Switzerland-based pharmaceutical manufacturing company, launched its AI-Enabled Route Scouting Service, an advanced digital solution designed to streamline synthetic route identification for novel APIs by combining Lonza’s global chemical supply chain intelligence with artificial intelligence capabilities from Elsevier’s Reaxys database. The service integrates extensive reaction datasets, process R&D expertise, and AI-driven recommendation engines to suggest optimized synthetic routes with improved efficiency and reduced development timelines, while also supporting sustainability by minimizing wasteful reaction screening. It is primarily used in early-stage drug development and process optimization for pharmaceutical manufacturing, helping companies reduce costs, improve scalability assessments, and accelerate time-to-market for new therapies.

In April 2024, Aptean Inc., a US-based software company, acquired Logility for $442.75 million. Through this acquisition, Aptean aims to strengthen its AI-driven supply chain planning capabilities and expand its cloud-based enterprise software portfolio by integrating Logility’s advanced demand forecasting and supply chain optimization technologies to improve end-to-end decision intelligence for customers. Logility Supply Chain Solutions Inc. is a US-based provider of AI-enabled supply chain planning software, offering solutions for demand forecasting, inventory optimization, sales and operations planning (S&OP), and end-to-end supply chain visibility.

Major companies operating in the artificial intelligence (AI) enabled pharma supply chain market are Microsoft Corporation; Amazon Web Services Inc.; Google LLC; IBM Corporation; Oracle Corporation; SAP SE; Infor Inc.; Coupa Software Inc.; Blue Yonder Group Inc.; Palantir Technologies Inc.; SAS Institute Inc.; Manhattan Associates Inc.; Kinaxis Inc.; o9 Solutions Inc.; The Descartes Systems Group Inc.; Flexport Inc.; Logility Inc.; C3.ai Inc.; project44 Inc.; FourKites Inc.; Aera Technology Inc.; ToolsGroup S.r.l.; Shippeo SAS; ParkourSC Inc.; FarEye Technologies Pvt. Ltd.

North America was the largest region in the artificial intelligence (AI) enabled pharma supply chain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) enabled pharma supply chain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) enabled pharma supply chain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI) enabled pharma supply chain market includes revenues earned by entities by providing services such as artificial intelligence-based demand forecasting, predictive maintenance, supplier risk management, and real-time pharmaceutical supply chain visibility services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The artificial intelligence (AI) enabled pharma supply chain market research report is one of a series of new reports that provides artificial intelligence (AI) enabled pharma supply chain market statistics, including artificial intelligence (AI) enabled pharma supply chain industry global market size, regional shares, competitors with a artificial intelligence (AI) enabled pharma supply chain market share, detailed artificial intelligence (AI) enabled pharma supply chain market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) enabled pharma supply chain industry. This artificial intelligence (AI) enabled pharma supply chain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.